Explore

Program Map

Start with a treatment, device, company, diagnosis, or trial ID. Each record keeps the source trail close to the claim.

161Main(26 active)
148Status checked
135Strong
320Backlog
More filters and sort (1 active)
135 records in Main database · 135 strong · 135 status checkedPage 1 of 3
Regeneron Pharmaceuticals · Gene Therapy · Approved
ApprovedTherapeuticStronger sources
Evidence
regulatory
Confidence
99%
Indications
Hearing LossSensorineural Hearing LossGenetic Hearing LossOTOF-Related Hearing Loss
Population
PediatricAdultCongenitalGenetic
Details
Fennec Pharmaceuticals · Small Molecule · Marketed
MarketedTherapeuticStronger sources
Evidence
regulatory
Confidence
98%
Indications
Cisplatin-Induced Hearing LossHearing Loss
Population
PediatricCisplatin Ototoxicity
Details
Apple · Hearing Aid/Software · Marketed
MarketedSoftware/NeurotechOTC Hearing AidsStronger sources
Evidence
regulatory
Confidence
97%
Indications
Hearing LossSensorineural Hearing LossAge-Related Hearing Loss
Population
AdultAge-RelatedPost-Lingual
Details
Neuromod Devices · Neuromodulation · Marketed
MarketedDeviceTinnitus NeuromodulationStronger sources
Evidence
regulatory
Confidence
97%
Indications
Tinnitus
Population
AdultTinnitus
Details
Eli Lilly and Company · Gene Therapy · Phase 2
ActiveTherapeuticStronger sources
Evidence
trial
Confidence
95%
Indications
Hearing LossSensorineural Hearing LossGenetic Hearing LossOTOF-Related Hearing Loss
Population
PediatricAdultCongenitalGenetic
Details
EssilorLuxottica · Hearing Aid/Software · Marketed
MarketedSoftware/NeurotechOTC Hearing AidsStronger sources
Evidence
regulatory
Confidence
95%
Indications
Hearing LossSensorineural Hearing LossAge-Related Hearing Loss
Population
AdultAge-RelatedPost-Lingual
Details
Cochlear · Cochlear/Auditory Implant · Marketed
MarketedDeviceCochlear ImplantsStronger sources
Evidence
company
Confidence
94%
Indications
Hearing LossSensorineural Hearing Loss
Population
PediatricAdultBilateralProfound
Details
Sensorion · Small Molecule · Phase 2
ActiveTherapeuticStronger sources
Evidence
company
Confidence
94%
Indications
Hearing LossSensorineural Hearing LossSudden Sensorineural Hearing LossCisplatin-Induced Hearing Loss
Population
AdultSudden / SSNHLCisplatin OtotoxicityCochlear Implant
Details
Sensorion · Gene Therapy · Phase 1/2
ActiveTherapeuticStronger sources
Evidence
trial
Confidence
94%
Indications
Hearing LossSensorineural Hearing LossGenetic Hearing LossOTOF-Related Hearing Loss
Population
PediatricCongenitalGeneticOTOF / DFNB9
Details
Envoy Medical · Cochlear/Auditory Implant · Phase 2/3
ActiveDeviceCochlear ImplantsStronger sources
Evidence
trial
Confidence
93%
Indications
Hearing LossSensorineural Hearing Loss
Population
AdultPost-LingualProfound
Details
MED-EL · Cochlear/Auditory Implant · Marketed
MarketedDeviceCochlear ImplantsStronger sources
Evidence
regulatory
Confidence
93%
Indications
Hearing LossSensorineural Hearing Loss
Population
PediatricAdultBilateralProfound
Details
Cochlear · Cochlear/Auditory Implant · Marketed
MarketedDeviceCochlear ImplantsStronger sources
Evidence
company
Confidence
92%
Indications
Hearing LossSensorineural Hearing LossCochlear Implant
Population
PediatricAdultCochlear ImplantImplantable Device
Details
Phonak · Hearing Aid/Software · Marketed
MarketedDeviceAI AudioStronger sources
Evidence
company
Confidence
92%
Indications
Hearing LossSensorineural Hearing LossAge-Related Hearing Loss
Population
AdultAge-RelatedPost-LingualModerate to Severe
Details
Rinri Therapeutics · Cell Therapy · Phase 1/2
ActiveTherapeuticStronger sources
Evidence
trial
Confidence
92%
Indications
Hearing LossSensorineural Hearing LossAge-Related Hearing LossAuditory Neuropathy
Population
AdultAge-RelatedAuditory Neuropathy
Details
AudioCure Pharma · Small Molecule · Phase 2
ActiveTherapeuticStronger sources
Evidence
trial
Confidence
91%
Indications
Hearing LossSensorineural Hearing LossSudden Sensorineural Hearing LossTinnitus
Population
AdultSudden / SSNHLTinnitus
Details
HIMSA · Fitting Software/Workflow · Marketed
MarketedSoftware/NeurotechFitting SoftwareStronger sources
Evidence
company
Confidence
91%
Indications
Hearing LossSensorineural Hearing Loss
Population
AdultPediatricClinical AudiologyFitting Workflow
Details
Auricle Inc. · Neuromodulation · Phase 2
ActiveDeviceTinnitus NeuromodulationStronger sources
Evidence
company
Confidence
90%
Indications
Tinnitus
Population
AdultTinnitus
Details
GN ReSound · Hearing Aid/Software · Marketed
MarketedDeviceAI AudioStronger sources
Evidence
company
Confidence
90%
Indications
Hearing LossSensorineural Hearing LossAge-Related Hearing Loss
Population
AdultAge-RelatedPost-LingualModerate to Severe
Details
Sound Pharmaceuticals · Small Molecule · Phase 3
ActiveTherapeuticStronger sources
Evidence
trial
Confidence
90%
Indications
Hearing LossSensorineural Hearing LossNoise-Induced Hearing LossTinnitus
Population
AdultNoise-InducedTinnitusCisplatin Ototoxicity
Details
MED-EL · Cochlear/Auditory Implant · Marketed
MarketedDeviceAuditory BCI / NeurotechStronger sources
Evidence
company
Confidence
86%
Indications
Hearing Loss
Population
Profound
Details
Envoy Medical · Active Middle Ear Implant · Marketed
MarketedDeviceBone Conduction & Middle EarStronger sources
Evidence
regulatory
Confidence
97%
Indications
Hearing LossSensorineural Hearing Loss
Population
AdultModerate to SeverePost-LingualActive Middle Ear Implant
Details
Cochlear · Cochlear/Auditory Implant · Marketed
MarketedDeviceBone Conduction & Middle EarStronger sources
Evidence
regulatory
Confidence
96%
Indications
Hearing LossConductive Hearing LossMixed Hearing LossSensorineural Hearing Loss
Population
PediatricAdultUnilateralBilateral
Details
Cochlear · BCI/Neurotech · Approved
ApprovedDeviceAuditory BCI / NeurotechStronger sources
Evidence
regulatory
Confidence
95%
Indications
Hearing LossAuditory Neuropathy
Population
AdultPost-LingualProfound
Details
MED-EL · Cochlear/Auditory Implant · Marketed
MarketedDeviceBone Conduction & Middle EarStronger sources
Evidence
regulatory
Confidence
95%
Indications
Hearing LossSensorineural Hearing LossConductive Hearing LossMixed Hearing Loss
Population
AdultUnilateralBilateralModerate to Severe
Details
Acousia Therapeutics GmbH · Small Molecule · Phase 2
ActiveTherapeuticStronger sources
Evidence
company
Confidence
93%
Indications
Hearing LossSensorineural Hearing LossAge-Related Hearing LossCisplatin-Induced Hearing Loss
Population
AdultAge-RelatedCisplatin Ototoxicity
Details
Cilcare SAS · Small Molecule · Phase 1/2
ActiveTherapeuticStronger sources
Evidence
trial
Confidence
92%
Indications
Hearing LossSensorineural Hearing LossHidden Hearing LossCochlear Synaptopathy
Population
AdultDiabetesCochlear SynaptopathyHidden Hearing Loss
Details
Cochlear · Bone Conduction / Middle-Ear Device · Marketed
MarketedDeviceBone Conduction & Middle EarStronger sources
Evidence
regulatory
Confidence
92%
Indications
Hearing LossConductive Hearing LossMixed Hearing LossSingle-Sided Deafness
Population
AdultPediatricBone Conduction ProcessorSingle Sided Deafness
Details
Cochlear · Cochlear/Auditory Implant · Marketed
MarketedDeviceBone Conduction & Middle EarStronger sources
Evidence
company
Confidence
92%
Indications
Hearing LossConductive Hearing LossMixed Hearing LossSensorineural Hearing Loss
Population
PediatricAdultUnilateralBilateral
Details
MED-EL · Bone Conduction / Middle-Ear Device · Marketed
MarketedDeviceBone Conduction & Middle EarStronger sources
Evidence
regulatory
Confidence
92%
Indications
Hearing LossConductive Hearing LossMixed Hearing LossSingle-Sided Deafness
Population
AdultPediatricNon Surgical Bone ConductionSingle Sided Deafness
Details
Neuracle Science Co., Ltd. · Biologic · Phase 1/2
ActiveTherapeuticStronger sources
Evidence
trial
Confidence
92%
Indications
Hearing LossSensorineural Hearing LossSudden Sensorineural Hearing LossCochlear Synaptopathy
Population
AdultSudden / SSNHLSensorineuralSalvage Therapy
Details
Earlens Corporation · Bone Conduction / Middle-Ear Device · Marketed
MarketedDeviceBone Conduction & Middle EarStronger sources
Evidence
regulatory
Confidence
91%
Indications
Hearing LossSensorineural Hearing LossConductive Hearing LossMixed Hearing Loss
Population
AdultClinical AudiologyMiddle Ear AssessmentTympanic Contact Device
Details
GeoAxon · Diagnostic · Marketed
MarketedDiagnosticDiagnosticsStronger sources
Evidence
company
Confidence
91%
Indications
Hearing LossSensorineural Hearing Loss
Population
AdultPediatricClinical AudiologyPortable Diagnostics
Details
Google · AI Audio/Speech Accessibility Software · Marketed
MarketedSoftware/NeurotechAI AudioStronger sources
Evidence
company
Confidence
91%
Indications
Hearing Loss
Population
AdultPediatricDeaf / Hard of HearingSpeech Enhancement
Details
PATH MEDICAL · Diagnostic · Marketed
MarketedDiagnosticDiagnosticsStronger sources
Evidence
regulatory
Confidence
91%
Indications
Hearing LossAuditory NeuropathyVestibular Disorders
Population
AdultPediatricCongenitalClinical Audiology
Details
Phonak · Prescription Hearing Aid · Marketed
MarketedDevicePrescription Hearing AidsStronger sources
Evidence
company
Confidence
91%
Indications
Hearing LossSensorineural Hearing LossSingle-Sided Deafness
Population
AdultPrescription Hearing AidReceiver In CanalRechargeable
Details
GN ReSound · Prescription Hearing Aid · Marketed
MarketedDevicePrescription Hearing AidsStronger sources
Evidence
company
Confidence
91%
Indications
Hearing LossSensorineural Hearing LossSingle-Sided Deafness
Population
AdultPrescription Hearing AidReceiver In CanalBehind The Ear
Details
Signia · Hearing Aid/Software · Marketed
MarketedDeviceAI AudioStronger sources
Evidence
company
Confidence
91%
Indications
Hearing LossSensorineural Hearing LossAge-Related Hearing Loss
Population
AdultAge-RelatedPost-LingualModerate to Severe
Details
Signia · Prescription Hearing Aid · Marketed
MarketedDevicePrescription Hearing AidsStronger sources
Evidence
company
Confidence
91%
Indications
Hearing LossSensorineural Hearing Loss
Population
AdultPrescription Hearing AidCompletely In CanalInstant Fit
Details
Eli Lilly and Company · Gene Therapy · Phase 1/2
ActiveTherapeuticStronger sources
Evidence
trial
Confidence
90%
Indications
Vestibular SchwannomaHearing Loss
Population
AdultUnilateralVestibular SchwannomaHearing Adjacent
Details
Apple · AI Audio/Speech Accessibility Software · Marketed
MarketedSoftware/NeurotechAI AudioStronger sources
Evidence
company
Confidence
90%
Indications
Hearing Loss
Population
AdultPediatricDeaf / Hard of HearingCaptioning
Details
Audioscan · Diagnostic/Fitting Verification · Marketed
MarketedDiagnosticDiagnosticsStronger sources
Evidence
company
Confidence
90%
Indications
Hearing LossSensorineural Hearing Loss
Population
AdultPediatricClinical AudiologyFitting Verification
Details
Ava · AI Audio/Speech Accessibility Software · Marketed
MarketedSoftware/NeurotechAI AudioStronger sources
Evidence
company
Confidence
90%
Indications
Hearing Loss
Population
AdultPediatricDeaf / Hard of HearingCaptioning
Details
ClearCaptions · AI Audio/Captioning · Marketed
MarketedSoftware/NeurotechAI AudioStronger sources
Evidence
company
Confidence
90%
Indications
Hearing Loss
Population
AdultOlder AdultDeaf / Hard of HearingCommunication Access
Details
Cochlear · Cochlear Implant Programming Software/Workflow · Marketed
MarketedSoftware/NeurotechFitting SoftwareStronger sources
Evidence
company
Confidence
90%
Indications
Hearing LossSensorineural Hearing LossCochlear Implant
Population
PediatricAdultPost Implant Programming
Details
Cochlear · Cochlear/Auditory Implant · Marketed
MarketedDeviceCochlear ImplantsStronger sources
Evidence
company
Confidence
90%
Indications
Hearing LossSensorineural Hearing LossCochlear Implant
Population
PediatricAdultPost Implant ProgrammingProfound
Details
Cochlear · Cochlear/Auditory Implant · Marketed
MarketedDeviceCochlear ImplantsStronger sources
Evidence
company
Confidence
90%
Indications
Hearing LossSensorineural Hearing LossCochlear Implant
Population
PediatricAdultCochlear ImplantPost Implant Programming
Details
Interacoustics · Diagnostic/Fitting Verification · Marketed
MarketedDiagnosticDiagnosticsStronger sources
Evidence
company
Confidence
90%
Indications
Hearing LossSensorineural Hearing Loss
Population
AdultPediatricClinical AudiologyFitting Verification
Details
Microsoft · AI Audio/Speech Accessibility Software · Marketed
MarketedSoftware/NeurotechAI AudioStronger sources
Evidence
company
Confidence
90%
Indications
Hearing LossCommunication Impairment
Population
AdultPediatricDeaf / Hard of HearingCaptioning
Details
Natus · Diagnostic/Fitting Verification · Marketed
MarketedDiagnosticDiagnosticsStronger sources
Evidence
company
Confidence
90%
Indications
Hearing LossSensorineural Hearing Loss
Population
AdultPediatricClinical AudiologyFitting Verification
Details